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The clinical implications of adult-onset
henoch-schonelin purpura
Warit Jithpratuck1, Yasmin Elshenawy2, Hana Saleh1, George Youngberg2, David S Chi1 and Guha Krishnaswamy1,3*

Abstract
Henoch-Schonlein Purpura (HSP) is a small vessel vasculitis mediated by IgA-immune complex deposition. It is
characterized by the clinical tetrad of non-thrombocytopenic palpable purpura, abdominal pain, arthritis and renal
involvement. Pathologically, it can be considered a form of immune complex-mediated leukocytoclastic vasculitis
(LCV) involving the skin and other organs. Though it primarily affects children (over 90% of cases), the occurrence
in adults has been rarely reported. Management often involves the use of immunomodulatory or immunesuppressive regimens.
Introduction
Henoch-Schonlein Purpura (HSP) is a small vessel vasculitis mediated by IgA-immune complex deposition. It
is characterized by the clinical tetrad of non-thrombocytopenic palpable purpura, abdominal pain, arthritis and
renal involvement [1]. Pathologically, it can be considered a form of leukocytoclastic vasculitis that can
involve not only the skin but other tissues as well.
Though it primarily affects children (over 90% of cases),
the occurrence in adults has been rarely reported (3.4 to
14.3 cases per million). This low incidence could be due
to either under-diagnosis or misdiagnosis.
Typically the disorder is commoner in males and may
follow an infectious illness [2]. In the cases reported in
children, the majority (of over 75%) of cases presented
with an eruption, while up to 66% presented with abdominal pain and close to 50% the cases demonstrated renal
involvement [2]. In children, the disorder is often selflimiting, while a more complicated course has been
described in adults, including a high incidence of renal
insufficiency developing in almost 50% of those patients
who showed renal involvement. It appears that patients
over 20 years old with bloody stools, relapsing disease
and persistent eruption are more likely to progress onto
complications [3]. Besides renal disease, cardiac, pulmonary, ocular, gastrointestinal and neurological complications have been described in this disorder. In that sense,
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this is truly a multisystem disease and may result in considerable morbidity and mortality in some patients. A
variety of disorders have been associated with HSP
including infection with Helicobacter pylori, hepatitis B
and certain malignancies. The following review describes
the course, complications and management of adultonset HSP.
Representative Case Studies
Case 1

A 56 year old man with prior history of hypertension and
adult onset diabetes mellitus presented with a skin eruption over the lower extremities of several weeks duration
(appearance of the eruption is shown in Figures 1A and
1B). This was accompanied by intermittent, crampy
lower abdominal pain and hematuria. The patient denied
fever, weight loss, diaphoresis, or arthralgia. He denied a
history of a preceding upper respiratory infection. Examination of the patient demonstrated a palpable purpuric
eruption over the lower extremities (Figure 1 A and 1B).
Urinalysis revealed proteinuria as well as microscopic
hematuria. His serum IgA levels was elevated (787 mg/dL
with a normal range of 70-400 mg/dL), while tests for
lupus, vasculitis and hepatitis were negative (Table 1). A
skin biopsy showed an inflammatory infiltrate around
superficial blood vessels with associated nuclear dust and
focal fibrinoid necrosis, consistent with leukocytoclastic
vasculitis. This was accompanied by deposition of IgA on
vascular walls seen on direct immunofluorescent staining,
a pathognomonic feature of HSP.

© 2011 Jithpratuck et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Table 1 Summary Clinical and Laboratory reviews
Case

Case 1

Case 2

Age (years)

56

57

Respiratory infection

No

No

Palpable purpuric
rash

Blistering rash

Crampy abdominal
pain

No

Arthritis/Arthralgia

No

No

Proteinuria g/24 hours

2.7

3.7

Microscopic hematuria

Yes

Yes

Eruption
Abdominal pain

White cell count
Platelet count

8.0 × 103 cells/mm3
3

13.8 × 103 cells/mm3

164 × 10 cells/mm

294 × 103 cells/mm3

Normal

Normal

PT/INR

3

ESR (mm/hour)

19

17

CRP(0-9.9) mg/L

11.1

220

Serum IgA mg/dL

787

272

C3/C4

Normal

Normal

Negative

Negative

Skin biopsy with
immunofluorescence

IgA deposition LCV

IgA deposition LCV

Renal biopsy with
immunofluorescence

N/A

IgA deposition

Colchicine and
Steroid

Colchicine and
Steroid

Autoantibodies

Treatment
LCV = leukocytoclastic vasculitis.

Figure 1 A 56 year old man with prior history of hypertension,
diabetes mellitus presented with a 4 week-duration skin
eruption over the lower extremities (Figure 1A and 1B). This
was accompanied by crampy lower abdominal pain and hematuria.
Punch biopsy of involved skin demonstrated leukocytoclastic
vasculitis, accompanied by deposition of IgA on vascular walls on
direct immunofluorescent staining.

Case 2

A 57 year old African American man with prior history
of cigarette smoking and alcohol abuse, hypertension,
coronary artery disease, and hyperlipidemia presented
with one week duration of blistering rash on both ankles
ascending to his groin area, and involving his hands.
This was associated with swelling in both hands and
feet without any abdominal pain. He denied any history
of antecedent upper respiratory tract infection. Examination revealed edema and a vesiculobullous rash in both
hands and feet that showed varied degrees of healing
(Figure 2A and 2B). Skin culture growth Stenotrophomonas maltophilia. Urinalysis revealed microscopic
hematuria and proteinuria. The spot urine protein-creatinine ratio was 3.7 which confirmed the diagnosis of
nephrotic syndrome. Other laboratory results were unremarkable, including hepatitis testing and serologies, with
the exception of an elevated CRP level of 220 mg/dL

(normal: 0-9.9 mg/dL: Table 1). Skin biopsy revealed the
presence of a perivascular inflammatory infiltrate in the
superficial dermal blood vessels, with nuclear dust and
focal fibrinoid necrosis, consistent with leukocytoclastic
vasculitis(LCV) (Figure 2C), accompanied by the deposition of IgA on vascular walls detected by direct immunofluorescent staining, a pathognomonic feature of HSP.
Renal biopsy revealed focal segmental endocapillary proliferation (Figure 2D) with positive immunofluorescent
staining for mesangial IgA (Figure 2E).
Pathogenesis

Henoch-Schonlein Purpura (HSP) is a small vessel vasculitis associated with immunoglobulin A(IgA) complex
deposition [2,4]. The immune complexes are composed
of IgA1 and IgA2 but only IgA1 is found in the inflammatory infiltrate of the disease [5]. Polymorphonuclear
leukocytes are recruited by chemotactic factors and
cause inflammation and necrosis of vessel walls (focal
fibrinoid necrosis) with occasional thrombosis, and with
associated red blood cell extravasation, consistent with a
form of leukocytoclastic vasculitis [6]. Skin biopsy
reveals polymorphonuclear cells or cell fragments
around small dermal blood vessels. Immune complexes
containing IgA and C3 have been found in skin, intestinal mucosa, joints, and kidneys which are the major
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Figure 2 Examination revealed edema and a vesiculobullous rash in both hands and feet that showed varied degrees of healing
(Figure 2A and B). Skin biopsy revealed the presence of a perivascular inflammatory infiltrate in the superficial dermal blood vessels, with
nuclear dust and focal fibrinoid necrosis, consistent with leukocytoclastic vasculitis (Figure 2C; Hematoxylin and eosin stain-40x objective),
accompanied by the deposition of IgA on vascular walls detected by direct immunofluorescent staining. Renal biopsy revealed focal segmental
endocapillary proliferation (Figure 2D; Periodic acid- Schiff stain-40x objective) with positive immunofluorescence testing for mesangial IgA
(Figure 2E; Immunoflurescence stain-40x objective).

organ sites involved in HSP [6]. In some cases reported
in the literature, overlap with polyangiitis or polyarteritisa nodosa-like disease have been reported, resulting in
a plethora of severe renal and pulmonary manifestations
(Figure 3). Although these cases are anecdotal, their
concurrence in a given patient suggests common pathways of immune complex-mediated vasculitis and resultant tissue injury.

second patient reported in this study). Other etiologies
proposed including allergens such as drugs, tumor antigens associated with malignancy and certain autoimmune
diseases [2,7-11]. Ninety percent of cases occur in children with a favorable outcome as stated earlier, suggesting either unique infectious pathogens common in
childhood or other unknown genetic/molecular factors.
Clinical Features

Etiology

The etiology of HSP remains unknown. Various antigenic
stimuli have been proposed to trigger this pathology,
including a broad spectrum of infectious agents such as
infections due to group A Streptococcus, Methicillinresistant Staphylococcus aureus, Helicobactor pylori, Parvovirus B19, Hepatitis B, Human Immunodeficiency
Virus, Stenotrophomonas maltophilia (as seen in the

Adult-onset HSP been described [4,8,12-20], (though
90% of cases still occur in children), with only 3.4 to
14.3 cases per million reported in the adult population
[4]. The diagnostic criteria for HSP are shown in Table
2. We used PubMed to review the English literature for
adult-onset HSP cases and the salient aspects of selected
cases along with our patients are shown in Table 3. The
clinical tetrad of presentations may be in any sequence,
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Figure 3 In some HSP cases reported in the literature, overlap with microscopic polyangiitis (MPA) or Polyarteritisa Nodosa (PAN)-like
disease have been reported, resulting in a plethora of severe renal and pulmonary manifestations.

with upper respiratory infection prior to the onset of
symptoms in about 36.4% [3]. A retrospective review of
250 adult patients with the disease reported on the following clinical findings [19]: a purpuric rash occurred in
96%, arthritis in 61%, GI disease in 48% and renal disease in 32% cases (99% of these cases demonstrating
proteinuria and 93% hematuria).
The skin is the most commonly involved site, often
starting with an erythematous, macular, or urticarial-type
eruption. The lesions then coalesce and evolve into the
typical ecchymoses and/or palpable purpura. The lesions
tend to appear in crops, with a symmetrical distribution
over gravity/pressure-dependent areas such as lower
limbs, trunk and upper extremities and frequently accompanied by edema on both extremities. Blistering and
hemorrhagic necrotic skin lesions occur in 35% [4,19].
Table 2 Diagnostic criteria for Henoch-Schonlein Purpura
The European League Against Rheumatism and Paediatric
Rheumatology European Society criteria –2006
Mandatory criterion: Palpable purpura with lower limb
predominance
Plus at least one of the following criteria:
1. Diffuse abdominal pain
2. IgA deposition in any biopsy
3. Arthritis/arthralgia
4. Renal involvement (hematuria and/or proteinuria)
American College of Rheumatology criteria–1990
Two or more of the following criteria are needed
1. Age 20 years or less at disease onset
2. Palpable purpura
3. Acute abdominal pain with gastrointestinal bleeding
4. Biopsy showing granulocytes in the walls of small arterioles or
venules in superficial layers of skin

Arthritis/arthralgia, the second most common manifestation, occurs in 61% of cases. It usually transient or
migratory, oligoarticular and non-deforming, but often
associated with periarticular swelling and tenderness
without effusion [4,19]
Gastrointestinal involvement is a typical feature of
HSP [19,21-23] and occurs in about 48% of cases. It is
caused by submucosal hemorrhage and edema or by
vasculitis. The most common presentation is colicky
pain or bleeding from an ulcer usually in the second
part of duodenum or ileum and/or the rectum. Gastrointestinal symptoms usually develop about one week
after the onset of the rash. In about 8% of cases, it can
be the first clinical presentation. In this situation, endoscopy and/or colonoscopy may help establish the diagnosis [4,19]. Intussusception may occur in elderly, often
presenting as an acute abdominal emergency and may
require urgent radiological evaluation for the diagnosis
[22]. HSP also has been linked with primary biliary cirrhosis and transient abnormalities of liver function tests.
As in our patients, an elevated IgA level occurs in about
60% and may point to the diagnosis, when the clinician
is faced with an unusual lower extremity eruption in the
setting of abdominal pain.
Renal impairment, the most serious complication,
ranges from microscopic hematuria to a full blown
nephrotic syndrome [19]. It is detected in 45-85%, with
a risk of progression to renal insufficiency in 30% of
adult-onset HSP. It is usually detected within two
months of the eruption, but sometimes may manifest as
late as six months after initial onset of the disease [3].
The most frequent pathology observed is a mesangial or
endocapillary proliferative glomerulonephritis [19].
Some studies have suggested that certain genetic
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Table 3 Selected reports of HSP in adult patients
Patient Age/
Clinical/Labs
(report) gender

Histological diagnosis

Treatment

Outcome

1

24/M

Purpuric rash, arthritis, abdominal pain, Hematuria
and proteinuria

Skin: LCV with IgA deposition
Mesangial IgA deposition

Glucocorticoids
Remission
Cyclophosphamide

2

68/M

Abdominal pain with diarrhea, purpuric rash,
elevated sedimentation rate

Skin: LCV with IgA deposition

None

3

77/M

Abdominal pain with diarrhea purpuric rash,
hematuria, elevated IgA level and sedimentation
rate

Skin: LCV with IgA deposition

Glucocorticoids
Remission
Cyclophosphamide

4

69/M

Pustular rash, abdominal pain myocardial infarction Endocapillary proliferative nephritis
with IgA deposition subendocardial
LCV

Glucocorticoids

Deceased

5

20/
M,76/F,
67/F

Purpuric rash, arthralgia, hematuria hemoptysis,
hypoxia, bilateral infiltrate

Skin: LCV with IgA deposition
pulmonary interstitial fibrosis

Glucocorticoids

Remission

6

20/F

Purpuric rash, arthralgia, hematuria, proteinuria,
seizure

Skin:LCV EEG: Transient focal
abnormality MRI: normal

Glucocorticoids
Dilantin

Remission

7*

56/M

Purpuric rash, crampy abdominal pain Hematuria,
proteinuria, elevated IgA level

Skin: LCV

Colchicine

Remission

8*

57/M

Blistering rash, hematuria, Nephrotic syndrome

Skin: LCV Endocapillary proliferative
nephritis mesangial IgA deposition

Glucocorticoids
Colchicine

Partial
remission

Spontaneous
remission

LCV: Leukocytoclastic vasculitis; M = Male; F = Female.
* Cases described in this report.

Unusual presentations include pulmonary involvement
[28-30], scrotal pain [31], central, peripheral nervous
system involvement and seizure [32-34] as well as cardiac involvement [35-37]. Pulmonary involvement can
manifest as diffuse alveolar hemorrhage and occasionally
as usual interstitial pneumonia or interstitial fibrosis.
There is an association between HSP and malignancy
[7,9,38], most commonly associated with solid tumors.
An evaluation for occult malignancy may therefore reasonable in adults (especially those above 40 years of age)
diagnosed with HSP.

less than 24 hours old and typically shows the classical
leukocytoclastic vasculitis in postcapillary venule with
IgA deposition. Renal biopsy should be performed in
case of uncertain diagnosis or severe renal impairment
such as nephrotic syndrome. Endoscopy and/or colonoscopy play a major role in helping diagnosis of the
patients with the gastrointestinal involvement as their
initial presentation.
No specific test is diagnostic for HSP. Elevated serum
IgA levels have been associated with HSP in about 60%
of cases [19]. Urine analysis can vary from microscopic
hematuria to nephritic-syndrome range proteinuria.
Coagulation studies and the platelet count are usually
normal. Inflammatory markers such as sedimentation
rate (ESR) and C reactive protein (CRP) levels are often
elevated. Serum level of insulin like growth factor (IGF)
and IGF binding protein 3 have been proposed as a
marker for determination of renal involvement as well
as the terminal complement complex (SC5b-9) level as a
surrogate for disease activity in HSP [41]. These need
independent confirmation.

Diagnosis

Treatment

There are two criteria proposed by American College of
Rheumatology [39] and the new criteria by European
League Against Rheumatism (EuLAR) and Pediatric
Rheumatology Society (PReS) [40] as listed in Table 2.
The diagnosis is usually based on clinical presentation
with tissue biopsy demonstrating leukocytoclastic vasculitis associated with IgA deposition (by immunofluorescence). Skin biopsy should be obtained from the lesion

Most cases of LCV are self-limited and may require little
or no intervention. In mild cases a nonsteroidal
anti-inflammatory agent may suffice. Colchicine is the
treatment of choice when the skin lesions are severe [42].
Colchicine inhibits polymorphonuclear leukocyte chemotaxis by inhibiting spindle formation, blocking lysosome
formation and stabilizing the lysosome membranes. The
suppressive effect of colchicine on the inflammatory

polymorphorphisms, such as those involving cytokine
genes (IL1 receptor antagonist, IL8 or IL1 beta) have
been associated with increased risk of renal involvement
[24-26]. Age of onset, the presence of renal impairment
and hematuria at the onset, abdominal pain as an initial
presentation, persistent eruption, renal pathology with
fibrinoid necrosis and the number of sclerotic glomeruli
are significant predictors of renal disease [3,19,27].
Other Complications
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Table 4 A summary of treatment options for
Henoch-Schonlein Purpura
Medication

Indication

Acetaminophen, NSAID

Mild eruption, arthritis

Colchicine

Severe or recurrent skin disease

Oral glucocorticoids

Severe eruption, cutaneous edema,
severe colicky abdominal pain,
scrotal and testicular involvement

Parenteral glucocorticoids

Same as oral; unable to tolerate
oral medications

High dose parenteral pulse
glucocorticoid

Nephrotic range proteinuria

High dose IV pulse glucocorticoids
combined with other forms of
immunosuppression (such as
cyclophosphamide)

Rapidly progressive
glomerulonephritis
Hemorrhagic involvement of lungs
or brain

Plasmapheresis and/or IGIV

Refractory to combination therapy
Massive hemorrhage in
gastrointestinal or other organs

IV = intravenous; IGIV = intravenous immunoglobulin.

pathway may explain its efficacy on the skin lesions. The
sulfone, Dapsone, has also been used to treat the vasculitic component of HSP; it has antioxidant scavenger
effects and may suppress the generation of toxic free
radicals in neutrophils. It also inhibits the synthesis of
IgG and IgA antibodies and prostaglandin D2 [43]. Glucocorticoids (such as prednisone at a dosage of 1-2 mg/
kg daily) have been used to treat gastrointestinal symptoms successfully [44].
Aggressive therapy with corticosteroids or cyclophosphamide has not been shown to be beneficial in reversing the renal disease except among patients with the
crescentic form of nephritis. Plasmapheresis and immunoglobulin have been used in refractory combination
therapy. These treatment options are summarized in
Table 4 [43,45-49].

Conclusion
HSP is a heterogeneous disorder manifesting in adults
with palpable purpura/skin vasculitis, hematuria and proteinuria, often with preserved renal function. The diagnosis can be easily missed: A high degree of suspicion and
requesting immuno-fluorescence studies in suspected
cases are mandatory to establishing the diagnosis. Skin
biopsy and immunofluorescence confirm the presence of
LCV with IgA deposition which is the pathognomonic
finding in HSP. Colchicine is a treatment of choice for
severe or recurrent LCV. Adults with HSP carry a different prognosis, and the development of hematuria may be
a harbinger for more serious complications such as
nephritic or nephrotic syndrome. Malignancy is common
in adult onset HSP and work up should be done to
exclude this possibility.
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